S. Kang

发表

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer

S. Lee, J. Seo, H. Kwon, 2013, Investigational New Drugs.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia

J. Choi, E. Kim, S. Kang, 2007, International journal of laboratory hematology.

Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.

D. Noh, H. Moon, N. Cho, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

M. Ahn, E. Cho, S. Shreeve, 2021 .

Progress in Early Detection and Management of Oral Dysplasia: Components for a Multifaceted Progression Risk Model

C. MacAulay, C. Poh, M. Rosin, 2011 .

Radiologic evaluation of bronchiectasis

D. H. Chung, S. Kang, J. D. Kim, 1987 .

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

K. Jung, J. Seo, H. Kim, 2017, Supportive Care in Cancer.

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

Y. Im, S. Im, K. Jung, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

M. Ryu, S. Rha, B. Ryoo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression

C.-H. Kim, K. Cheong, B-S Lee, 2014, Cell Death and Disease.